CHIP involves in non-small cell lung cancer prognosis through VEGF pathway

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• C-terminal Hsp70-interacting protein (CHIP) is an E3 ligase with known roles in various cancers.
• The VEGF pathway is a critical therapeutic target in non-small cell lung cancer (NSCLC).
• The specific role of CHIP and its relationship with the VEGF-VEGFR2 pathway in NSCLC remain largely unexplored.

Purpose of the Study:

• To investigate the clinical significance of CHIP in NSCLC.
• To elucidate the regulatory mechanism of CHIP in NSCLC, particularly concerning the VEGF-VEGFR2 pathway.

Main Methods:

• Quantitative reverse transcription PCR (QRT-PCR) to assess CHIP expression in NSCLC tissues.
• Chi-square, Kaplan-Meier, and Cox regression analyses to evaluate the association between CHIP expression and clinical parameters/prognosis.
• Enzyme-linked immunosorbent assay (ELISA) to measure VEGF secretion.
• Western blot to determine VEGFR2 protein levels.

Main Results:

• CHIP expression was significantly decreased in NSCLC tissues and correlated with advanced clinical stages, lymph node metastasis, and distant metastasis.
• Negative CHIP expression was associated with shorter patient survival, identifying CHIP as an independent prognostic biomarker.
• CHIP negatively regulated VEGF secretion, and CHIP overexpression reduced VEGFR2 protein levels.

Conclusions:

• CHIP functions as a potential prognostic biomarker for NSCLC patients.
• CHIP may play a role in NSCLC angiogenesis by modulating VEGF secretion and VEGFR2 expression.